Clinical evidence confirms Pep2Dia effects on postprandial glycemia in prediabetic subjects
ETAP-Lab had an instrumental position in Ingredia's projects and successfully predicted in mice the efficacy of Pep2Dia, a new bioactive ingredient expected to reduce postprandial blood sugar levels. Ingredia presented at Vitafoods (2019, 8th May 2019, Geneva) clinical evidence that Pep2Dia decreases postprandial blood sugar levels in a prediabetic population. The clinical studies were performed after ETAP-Lab showed a significant benefit of Pep2Dia. Indeed, when administered 15 minutes before a sugar shot in db/db